usage. Veterans Administration ad hoc interdisciplinary advisory committee on antimicrobial drug usage guidelines for peer review. JAMA 1977; 237:1001-2. 7. Kunin [2] stresses how these efforts have had limited success to date, considering that the level of antimicrobial resistance is now greater than it has been in the history of anti-infective agents and that we are witnessing a dramatic egress of the major pharmaceutical companies from the development of newer anti-infectives. The promotion of "antibiotic stewardship" is a critical role for the IDSA, and considerable efforts are ongoing. This guidance [3] is just one example of multiple current efforts. However, the IDSA is an organization of ∼9000 professionals and currently has no regulatory authority for "antibiotic stewardship" for the 11,000,000 licensed physicians and health care workers who are entitled to use antibiotics in any way that they feel is appropriate. The complex problem that these unregulated physicians and health care workers face is that of being asked to place a subset of their patients at risk for mortality due to curable infectious diseases by either withholding antibiotics or shortening the course of therapy. In addition, unlike in many other countries, they are asked to take this potentially high-risk, conservative medical approach in a nation in which medical law suits are frequent and risk avoidance strategies are highly valued by the general population. Against this background of biologically inevitable antimicrobial resistance, the failure of previous strategies to minimize microbial resistance development, the lack of significant antiinfective development through federal government agencies, and the egress of the major pharmaceutical companies from anti-infective development, the IDSA, after considerable research involving the top executives in the pharmaceutical industry, has suggested the financial incentives as described in its commentary [2] as an ad- ditional approach. In addition, it emphasizes the importance of educating the general population to influence our policy makers to take action against this developing crisis. Regarding Dr. Kunin's comments that the IDSA leadership has "conflicts of interest," it is our belief that the most appropriate solution to possible perceived conflicts of interest is disclosure. The readers can then decide for themselves whether the personal benefits that result from the IDSA leadership's interaction through shared research, professional education, and consultation with the pharmaceutical industry are their motivation or whether trying to stem a public health crisis and save the lives of thousands of children and adults dying from infections due to resistant organisms is their primary goal. 
Reply to Kunin: Infectious Diseases Society of America's Efforts to Contain Antibiotic Resistance
To the Editor-The leaders of the Infectious Diseases Society of America (IDSA) appreciate Dr. Kunin's [1] historical perspective on how the infectious diseases community has struggled to deal with antimicrobial resistance, and we share his desire to learn from that perspective as we move forward. However, we must take issue with the notion that the IDSA is late in addressing resistance and off-base in our recent efforts to stimulate anti-infective discovery as part of the solution to this problem. The IDSA has a long history of highlighting concerns about resistance and the importance of antimicrobial stewardship, including those activities, which Dr. Kunin proudly cites in his letter [1] , that occurred during his tenure as IDSA President in the mid1980s. The IDSA's recent growth in membership and our resultant enhanced ability to speak more forcefully and effectively about important public health policy matters during the past few years has allowed us to play a larger, more visible, and we believe more effective role than in the past. We are not late; we are just more capable. We strongly agree with Dr. Kunin on the need for more-effective efforts to promote better use of existing drugs. The IDSA joined with the Society For Healthcare Epidemiology of America to develop new antibiotic stewardship guidelines, and together, we are actively encouraging their implementation. Infectious diseases specialists should play a role in fostering appropriate use of antibiotics; however, we are only a few thousand among several hundreds of thousands of physicians and other health care providers who prescribe anti-infective agents. We are well armed with the knowledge to educate, but we are hampered by a health care delivery system in which patients expect more rather than less treatment and in which physicians are ever mindful of possible medical liability dangers. In addition, neither the IDSA nor individual infectious diseases specialists have any real authority to control the use of antibiotics; education and advocacy are our only real tools. Moreover, it must be acknowledged that tens of millions of dollars have been expended over the past several decades in trying to educate physicians and the public about the judicious use of antibiotics with only limited success, as evidenced by the increasing problem of drug resistance.
Even with improved use of antibiotics, we are still going to need new agents in the future. Clearly, combating antimicrobial resistance requires a multifaceted set of solutions. That is why we are also calling for a more robust research agenda involv-
